Education
About Us
Working with TipRanks
Follow Us
Curative Biotechnology (CUBT)
OTHER OTC:CUBT
CUBT Stock Chart & Stats
$0.01
<$0.01(11.32%)
At close: 4:00 PM EST
$0.01
<$0.01(11.32%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.03
Previous CloseN/A
Volume185.23K
Average Volume (3M)181.23K
Market Cap
$7.31M
Enterprise Value$10.44M
Total Cash (Recent Filing)$218.26K
Total Debt (Recent Filing)$3.11M
Price to Earnings (P/E)―
Beta-0.42
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,012,763,370
10 Day Avg. Volume67,116
30 Day Avg. Volume181,230
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-2.37
Price to Sales (P/S)0.00
P/FCF Ratio-11.36
Enterprise Value/Market Cap1.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-119.04
Enterprise Value/Ebitda-5.50
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CUBT FAQ
What was Curative Biotechnology’s price range in the past 12 months?
Curative Biotechnology lowest stock price was <$0.01 and its highest was $0.03 in the past 12 months.
What is Curative Biotechnology’s market cap?
Curative Biotechnology’s market cap is $7.31M.
When is Curative Biotechnology’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Curative Biotechnology’s earnings last quarter?
Currently, no data Available
Is Curative Biotechnology overvalued?
According to Wall Street analysts Curative Biotechnology’s price is currently Overvalued.
Does Curative Biotechnology pay dividends?
Curative Biotechnology does not currently pay dividends.
What is Curative Biotechnology’s EPS estimate?
Curative Biotechnology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Curative Biotechnology have?
Curative Biotechnology has 1,012,763,370 shares outstanding.
What happened to Curative Biotechnology’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Curative Biotechnology?
Currently, no hedge funds are holding shares in CUBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Curative Biotechnology
Curative Biotechnology, Inc. operates as a development-stage biomedical company. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include IMT504, a novel immune therapy to treat rabies and an adjuvant for vaccines; CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor; and Metformin Reformulation for the treatment of degenerative eye disease. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. The company was formerly known as Connectyx Technologies Holdings Group, Inc. and changed its name to Curative Biotechnology, Inc. in November 2020. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Boca Raton, Florida.
Technical Analysis
Traws Pharma
―
Sensei Biotherapeutics
―
AEON Biopharma
―
CERo Therapeutics Holdings
―
Polyrizon Ltd.
―